Here are five stocks added to the Zacks Rank #1 (Strong Buy) List today:ADMA Biologics, Inc. (ADMA) : This biopharmaceutical company has seen the Zacks Consensus Estimate for its current year earnings increasing 33.3% over the last 60 days.Inhibikase Therapeutics, Inc. (IKT) : This clinical-stage pharmaceutical company has seen the Zacks Consensus Estimate for its current year earnings increasing nearly 16% over the last 60 days.YPF Sociedad Anónima (YPF) : This international energy company engaging in the ...

Here are three stocks with buy rank and strong momentum characteristics for investors to consider today, January 24:ADMA Biologics, Inc. (ADMA) : This biopharmaceutical company has a Zacks Rank #1 and witnessed the Zacks Consensus Estimate for its current year earnings increasing 33.3% over the last 60 days.ADMA Biologics' shares gained 66.2% over the last three months compared with the S&P 500’s advance of 15.5%. The company possesses a Momentum Score of B.Canadian Imperial Bank of Commerce (CM) : This com ...

Here are five stocks added to the Zacks Rank #1 (Strong Buy) List today:ADMA Biologics, Inc. (ADMA) : This biopharmaceutical company has seen the Zacks Consensus Estimate for its current year earnings increasing 33.3% over the last 60 days.Potbelly Corporation (PBPB) : This restaurant franchise company has seen the Zacks Consensus Estimate for its current year earnings increasing 15.4% over the last 60 days.YPF Sociedad Anónima (YPF) : This energy company has seen the Zacks Consensus Estimate for its curren ...

Shares of Adma Biologics (ADMA) have gained 21.6% over the past four weeks to close the last trading session at $5.02, but there could still be a solid upside left in the stock if short-term price targets of Wall Street analysts are any indication. Going by the price targets, the mean estimate of $6.38 indicates a potential upside of 27.1%.The mean estimate comprises four short-term price targets with a standard deviation of $0.48. While the lowest estimate of $6 indicates a 19.5% increase from the current ...

Here are five stocks added to the Zacks Rank #1 (Strong Buy) List today:ADMA Biologics, Inc. (ADMA) : This biopharmaceutical company has seen the Zacks Consensus Estimate for its current year earnings increasing 33.3% over the last 60 days.Arcutis Biotherapeutics, Inc. (ARQT) : This biopharmaceutical company has seen the Zacks Consensus Estimate for its current year earnings increasing 10.4% over the last 60 days.Phreesia, Inc. (PHR) : This company that provides a SaaS-based software and payment platform fo ...

While "the trend is your friend" when it comes to short-term investing or trading, timing entries into the trend is a key determinant of success. And increasing the odds of success by making sure the sustainability of a trend isn't easy.The trend often reverses before exiting the trade, leading to a short-term capital loss for investors. So, for a profitable trade, one should confirm factors such as sound fundamentals, positive earnings estimate revisions, etc. that could keep the momentum in the stock aliv ...

4Q 2023 Preliminary Unaudited Total Revenue of $72-74 Million FY 2023 Preliminary Unaudited Total Revenue of $256-258 Million FY 2024 and 2025 Total Revenue Guidance Increased to More than $320 Million and $370 Million, Respectively FY 2024 Net Income Expected to Exceed $60 Million and Adjusted EBITDA(1) Expected to be $85 Million Growth Opportunities Targeting Manufacturing and New Pipeline Hyperimmune Globulin to Advance During 2024 RAMSEY, N.J. and BOCA RATON, Fla., Jan. 08, 2024 (GLOBE NEWSWIRE) -- ADM ...

ADMA Biologics, Inc. (NASDAQ:ADMA) Q3 2023 Earnings Conference Call November 8, 2023 4:30 PM ET Company Participants Skyler Bloom - Head, Business Development & Corporate Strategy Adam Grossman – President & CEO Brian Lenz - EVP, CFO & GM, ADMA BioCenters Conference Call Participants Kristen Kluska - Cantor Fitzgerald Anthony Petrone - Mizuho Group Gary Nachman - Raymond James Operator Good afternoon, and welcome to the ADMA Biologics Third Quarter 2023 Financial Results and Corporate Update Conference Call ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ________ to ________ Commission file number 001-36728 ADMA BIOLOGICS, INC. (Exact Name of Registrant as Specified in Its Charter) Delaware 56-2590442 (Sta ...

ADMA Biologics, Inc. (NASDAQ:ADMA) Q2 2023 Earnings Conference Call August 9, 2023 4:30 PM ET Company Participants Skyler Bloom - Senior Director, Business Development & Corporate Strategy Adam Grossman - Co-Founder, President, CEO & Director Brian Lenz - EVP, CFO & GM, ADMA BioCenters Conference Call Participants Gary Nachman - Raymond James & Associates Anthony Petrone - Mizuho Securities Kristen Kluska - Cantor Fitzgerald Operator Good afternoon, and welcome to the ADMA Biologics Second Quarter 2023 Fina ...